Database on Funding Activities for Personalised Medicine (PM) Research Has Been Launched

The International Consortium for Personalised Medicine (ICPerMed) database, launched on 5 July 2018, gives an overview on the actions in the field of personalised medicine performed in the ICPerMed member states and may assist interested users in finding suitable funding opportunities and information about potential funders in their respective country and/or region.

The access to the data requires simple registration here.

The first ICPerMed Conference ‘Personalised Medicine in Action’ will take place on 20-21 November 2018 in Berlin, Germany. Registration is now open.

Sources: ICPerMed, Euresearch


PhD positions in Co-Fund project on Personalized medicine in chronic diseases with a focus on diabetes

The University Medical Center Groningen, the Netherlands, is about to start a H2020 supported Co-Fund project on Personalized medicine in chronic diseases with a focus on diabetes. The project is an educational programme where PhD Fellows are going to be trained on the topic of personalized medicine mainly in diabetes. They will be offered an attractive teaching programme on personalized medicine and have the opportunity to obtain a PhD in 4 years.
PhD fellows who will be trained should come from outside the Netherlands to enhance mobility of students in Europe and beyond. Students from all parts of the world are thus eligible. We will start the program in September and we have now started to recruit candidates. Students with a background in medicine, biology, epidemiology, pharmacy etc can apply for a position.
More information can be found on the UMCG website and on the application page.

Innovative Medicines Initiative: Publication of IMI1 and IMI2 evaluations

The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.

The experts conclude that IMI programme ‘remains relevant and justified’ and that ‘positive contributions on the drug development process have been realised’. Positive points recognised in the reports include:

- the IMI role in the creation of collaborative research networks that have enhanced trust between partners from different sectors, and triggered a mind shift as partners came to understand each other’s needs;
- the quality of the research emerging from IMI projects;
- the creation of important resources and tools for drug development, some of which are already being used by researchers in their daily work.

The reports also note that 90% of the people who responded to the online survey agreed that the EU should cooperate with industry in the context of a public-private partnership on health.

Suggestions for improvement concern performance indicators, increasing the involvement of SMEs as well as dissemination and communication of the projects' results.

Read the European Commission's press release on the evaluation
Read the new IMI brochure on results and impacts

Source: IMI

Swiss wins 2017 Nobel Prize in chemistry

Jacques Dubochet of Switzerland's University of Lausanne has been awarded this year’s Nobel prize in chemistry together with two other scientists from Britain and the United States.

Announcing the winners on Wednesday, the Royal Swedish Academy of Sciences said the three scientists helped develop cryo-electron microscopy - a method to have detailed images of life’s complex machineries in atomic resolution.

Dubochet, born in 1942, is a honorary professor of biophysics at Lausanne University and worked at Basel and Geneva Universities.

Innovative Medicines Initiative (IMI) 2 Call 13: Indicative Topics Published

IMI 2 has just published a list of indicative topics for the call 13 which is foreseen to be launched before the end of the year.

The following topics are under consideration for inclusion in future IMI calls for proposals:

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- CONCEPTION - continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Federated and privacy-preserving machine learning in support of drug discovery
- Pilot programme on a clinical compound bank for repurposing. This programme includes the following topics: Cardiovascular diseases and diabetes, Respiratory diseases, Neurodegenerative diseases and Rare/orphan diseases

Source: IMI2

Show more posts

Stacks Image p6729_n47
Stacks Image p6729_n398
Stacks Image p6729_n51
Stacks Image p6729_n349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.